SK Biopharmaceuticals Future Growth
Future criteria checks 6/6
SK Biopharmaceuticals is forecast to grow earnings and revenue by 77.2% and 21.8% per annum respectively. EPS is expected to grow by 77.8% per annum. Return on equity is forecast to be 33.8% in 3 years.
Key information
77.2%
Earnings growth rate
77.8%
EPS growth rate
Pharmaceuticals earnings growth | 35.9% |
Revenue growth rate | 21.8% |
Future return on equity | 33.8% |
Analyst coverage | Good |
Last updated | 09 Aug 2024 |
Recent future growth updates
Recent updates
Does This Valuation Of SK Biopharmaceuticals Co., Ltd. (KRX:326030) Imply Investors Are Overpaying?
May 22SK Biopharmaceuticals Co., Ltd. (KRX:326030) Not Lagging Industry On Growth Or Pricing
Apr 09Is SK Biopharmaceuticals (KRX:326030) A Risky Investment?
Feb 27We're Not Worried About SK Biopharmaceuticals' (KRX:326030) Cash Burn
Mar 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 831,039 | 237,748 | 199,871 | 204,125 | 14 |
12/31/2025 | 653,261 | 125,354 | 119,183 | 125,923 | 16 |
12/31/2024 | 533,243 | 79,717 | 82,600 | 71,960 | 4 |
3/31/2024 | 408,082 | -17,682 | -29,943 | -27,243 | N/A |
12/31/2023 | 354,892 | -32,883 | -97,451 | -94,201 | N/A |
9/30/2023 | 290,903 | -83,502 | -124,549 | -119,901 | N/A |
6/30/2023 | 289,399 | -84,533 | -146,546 | -141,462 | N/A |
3/31/2023 | 265,819 | -106,594 | -157,666 | -151,460 | N/A |
12/31/2022 | 246,179 | -139,431 | -165,881 | -159,920 | N/A |
9/30/2022 | 414,148 | -48,445 | -194,822 | -188,994 | N/A |
6/30/2022 | 349,264 | -77,756 | -102,358 | -96,193 | N/A |
3/31/2022 | 319,801 | -99,351 | -118,776 | -113,474 | N/A |
12/31/2021 | 418,645 | 64,846 | -98,864 | -92,872 | N/A |
9/30/2021 | 203,992 | -40,396 | -38,937 | -30,581 | N/A |
6/30/2021 | 183,964 | -59,196 | -172,311 | -160,196 | N/A |
3/31/2021 | 162,060 | -51,828 | -197,006 | -181,777 | N/A |
12/31/2020 | 25,999 | -247,414 | -225,063 | -210,726 | N/A |
9/30/2020 | 10,115 | -242,367 | -284,100 | -270,297 | N/A |
6/30/2020 | 6,274 | -229,537 | -260,554 | -247,808 | N/A |
3/31/2020 | 10,717 | -212,544 | -220,142 | -206,493 | N/A |
12/31/2019 | 123,852 | -71,519 | -95,162 | -81,335 | N/A |
12/31/2018 | 1,099 | -138,222 | -142,717 | -141,281 | N/A |
12/31/2017 | N/A | -98,463 | N/A | -98,343 | N/A |
12/31/2016 | 89,928 | -30,361 | N/A | -48,941 | N/A |
12/31/2015 | 71,417 | -28,949 | N/A | -28,717 | N/A |
12/31/2014 | 72,441 | -37,049 | N/A | -40,336 | N/A |
12/31/2013 | 60,455 | -41,002 | N/A | -39,064 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A326030 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: A326030 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: A326030 is expected to become profitable in the next 3 years.
Revenue vs Market: A326030's revenue (21.8% per year) is forecast to grow faster than the KR market (10% per year).
High Growth Revenue: A326030's revenue (21.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A326030's Return on Equity is forecast to be high in 3 years time (33.8%)